Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Seagen Inc.
Merck Sharp & Dohme LLC
First Affiliated Hospital of Zhejiang University
Lisata Therapeutics, Inc.
CSPC Ouyi Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
Galectin Therapeutics Inc.
National Cancer Institute (NCI)
Peking University
Alliance for Clinical Trials in Oncology
Stanford University
Simcere Pharmaceutical Co., Ltd